Join PER® September 15th for the New York Advanced Practice Collaborative Meeting! Directed toward NP/PAs, this meeting blends presentations on cutting-edge information with panel discussions to enhance learning.

Safety of Monoclonal Antibodies in Myeloma

KEITH STEWART, MB, CHB
Wednesday, February 01, 2017

Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.

While infusion reactions can occur, pre-medication is recommended. Also, reactions do not usually persist past the first infusion. For daratumumab, these reactions can also affect the upper respiratory system. Also in daratumumab, the agent can affect red cell cross-matching for transfusion. Therefore, all cross-matching should take place before infusions.

To learn more about these treatments, watch Monoclonal Antibodies in Multiple Myeloma.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.